drugset / Trial / NCT05445297
Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter
Phase 4
Completed
60 enrolled
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RandomizedParallel-groupSingle-blindTreatment
Summary
Patients hospitalized with paroxysmal atrial fibrillation and flutter to restore sinus rhythm will be randomized into two groups: one will be cardioversion with refralon and the other with amiodarone
Timeline
- Start
- 2022-01-26
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amiodarone | Small molecule | 100 mg | Intravenous |
| Subject | Refralon | Unknown | 10 ug/kg | Intravenous |